Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pneumococcal Vaccination in the Elderly Needs Government Support
September 25, 2006
- Kowa Pharmaceutical Aims for Sales of \74.8 Bil. in FY2007
September 25, 2006
- R&D NEWS IN BRIEF
September 25, 2006
- Once-weekly Osteoporosis Drug Both Effective and Convenient
September 25, 2006
- Dr Bale Discusses Current Top Priorities at IFPMA
September 25, 2006
- Korosho to Promote Domestic Vaccine Development, Blood Donation
September 25, 2006
- Aging, Vitamin C Deficiency Contribute to COPD
September 25, 2006
- Global Partnerships Essential in BT Industry: Dr Mimura
September 25, 2006
- Online Processing of Medical Bills to Expand in April 2007
September 25, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 25, 2006
- JETRO BIOLINK FORUM 2006:Importance of Alliances Stressed
September 25, 2006
- NWE PRODUCTS
September 25, 2006
- BUSINESS NEWS IN BRIEF
September 25, 2006
- Sekisui Chemical to Acquire Daiichi Pure Chemicals
September 25, 2006
- Sawai to Reorganize Its Hansha by Region
September 25, 2006
- Daiichi Sankyo to Transfer All Shares of DRL to Fuji Film
September 25, 2006
- TOPICS Janssen-Cilag, Ortho Biotech Receive 2006 Prix Galien for Velcade
September 25, 2006
- MEDICAL DEVICE NEWS IN BRIEF
September 25, 2006
- Daiko to Focus on R&D Due to Difficulty in Making All Strengths Available
September 25, 2006
- Kobayashi Pharm. Announces 3-Pronged Management Strategy
September 25, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…